Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.

Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y.

J Clin Oncol. 2019 Dec 4:JCO1901674. doi: 10.1200/JCO.19.01674. [Epub ahead of print]

PMID:
31800340
2.

Reply to J. Delyon et al.

Abu-Sbeih H, Ali FS, Owen DH, Ricciuti B, Naqash AR, Wang Y.

J Clin Oncol. 2019 Dec 20;37(36):3564-3565. doi: 10.1200/JCO.19.02133. Epub 2019 Oct 9. No abstract available.

PMID:
31596634
3.

Metastatic Adrenocortical Carcinoma: a Single Institutional Experience.

Owen DH, Patel S, Wei L, Phay JE, Shirley LA, Kirschner LS, Schmidt C, Abdel-Misih S, Brock P, Shah MH, Konda B.

Horm Cancer. 2019 Dec;10(4-6):161-167. doi: 10.1007/s12672-019-00367-0. Epub 2019 Aug 29.

PMID:
31468469
4.

Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.

Li M, Spakowicz D, Burkart J, Patel S, Husain M, He K, Bertino EM, Shields PG, Carbone DP, Verschraegen CF, Presley CJ, Otterson GA, Kendra K, Owen DH.

J Cancer Res Clin Oncol. 2019 Oct;145(10):2541-2546. doi: 10.1007/s00432-019-02982-4. Epub 2019 Jul 31.

5.

Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.

Owen DH, Williams TM, Bertino EM, Mo X, Webb A, Schweitzer C, Liu T, Roychowdhury S, Timmers CD, Otterson GA.

Lung Cancer. 2019 Aug;134:167-173. doi: 10.1016/j.lungcan.2019.06.017. Epub 2019 Jun 17.

PMID:
31319977
6.

DLL3: an emerging target in small cell lung cancer.

Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K.

J Hematol Oncol. 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2. Review.

7.

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.

Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y.

J Clin Oncol. 2019 Oct 20;37(30):2738-2745. doi: 10.1200/JCO.19.00320. Epub 2019 Jun 4.

8.

KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.

Owen DH, Konda B, Sipos J, Liu T, Webb A, Ringel MD, Timmers CD, Shah MH.

J Natl Compr Canc Netw. 2019 May 1;17(5):409-413. doi: 10.6004/jnccn.2019.7292.

9.

Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?

Owen DH, Otterson GA.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4069-S4072. doi: 10.21037/jtd.2018.09.102. No abstract available.

10.

Transfusion rates with intravenous tranexamic acid in total hip arthroplasty performed using the direct anterior approach.

Free MD, Owen DH, Pascoe E, Allen P, Yang L, Harvie P.

Hip Int. 2019 Sep;29(5):511-515. doi: 10.1177/1120700018811310. Epub 2018 Nov 27.

PMID:
30477358
11.

Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer.

Owen DH, Wei L, Bertino EM, Edd T, Villalona-Calero MA, He K, Shields PG, Carbone DP, Otterson GA.

Clin Lung Cancer. 2018 Nov;19(6):e893-e900. doi: 10.1016/j.cllc.2018.08.008. Epub 2018 Aug 22.

12.

Direct Anterior Approach Total Hip Arthroplasty: An Adjunct to an Enhanced Recovery Pathway: Outcomes and Learning Curve Effects in Surgeons Transitioning From Other Surgical Approaches.

Free MD, Owen DH, Agius PA, Pascoe EM, Harvie P.

J Arthroplasty. 2018 Nov;33(11):3490-3495. doi: 10.1016/j.arth.2018.06.033. Epub 2018 Jul 4.

PMID:
30055885
13.

Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma.

Harding JJ, Abu-Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, Capanu M, Do R, Kemeny NE, O'Reilly EM, Saltz LB, Abou-Alfa GK.

J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024.

PMID:
29295881
14.

Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response.

Owen DH, Alexander AJ, Konda B, Wei L, Hemminger JA, Schmidt CR, Abdel-Misih SRZ, Dillhoff ME, Sipos JA, Kirschner LS, Shah MH.

Oncotarget. 2017 Oct 24;8(61):104046-104056. doi: 10.18632/oncotarget.22001. eCollection 2017 Nov 28.

15.

Attitudes and perceptions towards novel objective measures of ARV-based vaginal ring use: Results from a global stakeholder survey.

Stalter RM, Tharaldson J, Owen DH, Okumu E, Moench T, Mack N, Tolley EE, MacQueen KM.

PLoS One. 2017 Jul 14;12(7):e0180963. doi: 10.1371/journal.pone.0180963. eCollection 2017.

16.

Factors predictive of patient outcome following total wrist arthrodesis.

Owen DH, Agius PA, Nair A, Perriman DM, Smith PN, Roberts CJ.

Bone Joint J. 2016 May;98-B(5):647-53. doi: 10.1302/0301-620X.98B5.35638.

PMID:
27143736
17.

Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings.

Stalter RM, Moench TR, MacQueen KM, Tolley EE, Owen DH; Consortium for Ring Adherence.

J Int AIDS Soc. 2016 May 2;19(1):20746. doi: 10.7448/IAS.19.1.20746. eCollection 2016. Review.

18.

In vivo release of levonorgestrel from Sino-implant (II) — an innovative comparison of explant data.

Callahan RL, Taylor D, Jenkins DW, Owen DH, Cheng L, Cancel AM, Dorflinger LJ, Steiner MJ.

Contraception. 2015 Oct;92(4):350-5. doi: 10.1016/j.contraception.2015.06.028. Epub 2015 Jul 2.

19.

Towards the development of a longer-acting injectable contraceptive: past research and current trends.

Halpern V, Stalter RM, Owen DH, Dorflinger LJ, Lendvay A, Rademacher KH.

Contraception. 2015 Jul;92(1):3-9. doi: 10.1016/j.contraception.2015.02.014. Epub 2015 Mar 4. Review.

20.

An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings.

MacQueen KM, Tolley EE, Owen DH, Amico KR, Morrow KM, Moench T, Friend DR, Friedland B.

J Int AIDS Soc. 2014 Sep 8;17(3 Suppl 2):19158. doi: 10.7448/IAS.17.3.19158. eCollection 2014. Review.

21.
22.

Designing a multipurpose technology for acceptability and adherence.

Tolley EE, Morrow KM, Owen DH.

Antiviral Res. 2013 Dec;100 Suppl:S54-9. doi: 10.1016/j.antiviral.2013.09.029. Epub 2013 Nov 1. Review.

23.

Development and implementation of a quality assurance program for a hormonal contraceptive implant.

Owen DH, Jenkins D, Cancel A, Carter E, Dorflinger L, Spieler J, Steiner MJ.

Contraception. 2013 Apr;87(4):473-9. doi: 10.1016/j.contraception.2012.07.010. Epub 2012 Aug 24.

PMID:
22921687
24.

Dilution of microbicide gels with vaginal fluid and semen simulants: effect on rheological properties and coating flow.

Lai BE, Xie YQ, Lavine ML, Szeri AJ, Owen DH, Katz DF.

J Pharm Sci. 2008 Feb;97(2):1030-8.

PMID:
17724667
25.

Optical imaging and analysis of human vaginal coating by drug delivery gels.

Henderson MH, Couchman GM, Walmer DK, Peters JJ, Owen DH, Brown MA, Lavine ML, Katz DF.

Contraception. 2007 Feb;75(2):142-51. Epub 2006 Oct 31.

26.

Temperature and pH sensitive hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles.

Gupta KM, Barnes SR, Tangaro RA, Roberts MC, Owen DH, Katz DF, Kiser PF.

J Pharm Sci. 2007 Mar;96(3):670-81. Erratum in: J Pharm Sci. 2009 Mar;98(3):1198.

PMID:
17154368
27.

Biophysical analysis of prototype microbicidal gels.

Owen DH, Peters JJ, Kieweg SL, Geonnotti AR, Schnaare RL, Katz DF.

J Pharm Sci. 2007 Mar;96(3):661-9.

PMID:
17131365
28.
29.

Effect of temperature and pH on contraceptive gel viscosity.

Owen DH, Peters JJ, Lavine ML, Katz DF.

Contraception. 2003 Jan;67(1):57-64.

PMID:
12521660
30.

Comparison of the rheological properties of Advantage-S and Replens.

Owen DH, Peters JJ, Katz DF.

Contraception. 2001 Dec;64(6):393-6.

PMID:
11834239
31.

Rheological properties of contraceptive gels.

Owen DH, Peters JJ, Katz DF.

Contraception. 2000 Dec;62(6):321-6.

PMID:
11239620
32.

Factors influencing nonoxynol-9 permeation and bioactivity in cervical mucus.

Owen DH, Dunmire EN, Plenys AM, Katz DF.

J Control Release. 1999 Jun 28;60(1):23-34.

PMID:
10370168
33.

A vaginal fluid simulant.

Owen DH, Katz DF.

Contraception. 1999 Feb;59(2):91-5. Review.

PMID:
10361623
34.

The utility of motion parallax information for the perception and control of heading.

Frey BF, Owen DH.

J Exp Psychol Hum Percept Perform. 1999 Apr;25(2):445-60.

PMID:
10205862
35.

Sampling factors influencing accuracy of sperm kinematic analysis.

Owen DH, Katz DF.

J Androl. 1993 May-Jun;14(3):210-21.

36.

The Privy Council and the professional foul.

Owen DH.

Med Leg J. 1992;60 ( Pt 2):128-38; discussion 139-41. No abstract available.

PMID:
1635514
37.

Evidence for the function of hyperactivated motility in sperm.

Suarez SS, Katz DF, Owen DH, Andrew JB, Powell RL.

Biol Reprod. 1991 Feb;44(2):375-81.

PMID:
2009336
38.
39.

Functional optical invariants: a new methodology for aviation research.

Warren R, Owen DH.

Aviat Space Environ Med. 1982 Oct;53(10):977-83.

PMID:
7150160
40.

Optical information for detecting loss in one's own forward speed.

Owen DH, Warren R, Jensen RS, Mangold SJ, Hettinger LJ.

Acta Psychol (Amst). 1981 Aug;48(1-3):203-13.

PMID:
7304228
41.

Laterality differences in sensitivity to line orientation as a function of adaptation duration.

Tei BE, Owen DH.

Percept Psychophys. 1980 Nov;28(5):479-83. No abstract available.

PMID:
7208259
42.

Bias-free improvement in wine discrimination.

Owen DH, Machamer PK.

Perception. 1979;8(2):199-209.

PMID:
471683
43.

Developmental generality of a form recognition strategy.

Owen DH.

J Exp Child Psychol. 1971 Apr;11(2):194-205. No abstract available.

PMID:
5578241
44.

The metrics of visual form: methodological dyspepsia.

Brown DR, Owen DH.

Psychol Bull. 1967 Oct;68(4):243-59. No abstract available.

PMID:
6077745

Supplemental Content

Support Center